Summary: In 78 adults with type 2 diabetes randomised 2:1 to the novel GLP-1 analogue Ebenatide versus placebo (China, single centre), Ebenatide produced greater reductions in HbA1c and time-above-range and better time-in-range than placebo at Week 24 (all p<0.05). This between-group advantage was no longer present at Week 52, after the placebo arm had crossed over to active drug. Within the Ebenatide arm, weight, BMI, body fat and waist-to-height ratio fell, and adverse events were limited to gastrointestinal reactions.
PICO Summary
| Element | Detail |
|---|---|
| Population | 78 adults with type 2 diabetes enrolled, 76 completed; randomised, prospective, single-centre interventional trial (Nanjing, China). NCT05990374. |
| Intervention | Ebenatide, a novel glucagon-like peptide-1 analogue, for 52 weeks (n=52). Continuous glucose monitoring and body-composition analysis performed. |
| Comparison | Placebo for 24 weeks, then crossover to Ebenatide for the subsequent 28 weeks (n=24). 2:1 allocation ratio. |
| Outcome | Versus placebo, Ebenatide gave greater reductions in HbA1c and time-above-range and improved time-in-range at Week 24 (p<0.05), with no between-group difference at Week 52. Within the Ebenatide arm versus baseline: lower HbA1c, mean blood glucose, time-above-range and glucose SD with improved time-in-range at Weeks 24 and 52 (p<0.05); reduced triglyceride-glucose index at Week 52 (p<0.01); and significant falls in weight, BMI, body fat and waist-to-height ratio (p<0.05). Serum amylase and lipase rose and blood pressure and haemoglobin fell at Weeks 24 and 52 (p<0.05). No effect sizes, 95% CIs or ARR/NNT were reported in the abstract. Adverse events were confined to gastrointestinal reactions. |
Expert Commentary
This is an early-phase, exploratory signal rather than confirmation of efficacy. The randomised placebo-controlled comparison is genuinely informative only at Week 24, where Ebenatide beat placebo on HbA1c, time-above-range and time-in-range. By Week 52 the placebo arm had crossed over to active drug, so the loss of a between-group difference reflects that design choice and should not be read as fading benefit; the persuasive within-arm improvements at Week 52 are uncontrolled and cannot be separated from regression, lifestyle or trial effects. The trial is small, single-centre and open in places, and the abstract reports only directional significance thresholds without effect sizes, confidence intervals, or numbers needed to treat, which limits any judgement of clinical magnitude. The one limitation I would weigh most heavily is that no comparator GLP-1 receptor agonist was tested, so we cannot say whether Ebenatide adds anything over established agents that already deliver glycaemic and weight benefit. The rise in serum amylase and lipase deserves monitoring and the fall in haemoglobin warrants explanation. Can I use this with my patients? Not yet; for a person with type 2 diabetes seeking weight and glycaemic gains I would still reach for an approved GLP-1 agent. I would like to see a larger, multicentre active-comparator trial with reported effect sizes before this molecule earns a place in practice.
References
Xu CL, Kong XC, Liu XM, Xu XH, Liu BL, Ma JH. Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;16:1622526. doi:10.3389/fendo.2025.1622526
